Suloctidil was a sulfur-containing aminoalcohol that was brought to market in the early 1970s as a vasodilator by Continental Pharma, a Belgian company.[1]: 118–121 [2][3]

Suloctidil
Clinical data
ATC code
Identifiers
  • 1-[4-(isopropylthio)phenyl]-2-(octylamino)propan-1-ol
CAS Number
PubChem CID
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.053.920 Edit this at Wikidata
Chemical and physical data
FormulaC20H35NOS
Molar mass337.57 g·mol−1
  (verify)

Continental was bought by Monsanto in 1984, primarily on the promise of sales of suloctidil, which was approved in Europe at the time, but not in the US.[4] However, in 1985 Monsanto halted development and withdrew the drug worldwide following reports of liver toxicity.[5]: 251 

References

edit
  1. ^ Hladovec J (1989). Antithrombotic Drugs in Thrombosis Models. CRC Press. ISBN 978-0-8493-5162-4.
  2. ^ Roncucci R, Roba J, Lambelin G, Ferenczi M, Blaton V, Vandamme D, Peeters H (March 1975). "Potential antilipolytic activity of suloctidil". Die Naturwissenschaften. 62 (3): 141–2. Bibcode:1975NW.....62..141R. doi:10.1007/bf00623284. PMID 1240601. S2CID 29484315.
  3. ^ BE granted 739678, Buu-Hoi NP, Lambelin G, Roba J, Jacques G, Gillet C, "1-Subst-phenyl-2-amino-ethanols useful as beta adrenergic agents peripheral vasodilators and hypotensive agents" 
  4. ^ "Monsanto's $150 mil. Life Sciences Research Center". Pharma & Medteck Business Intelligence. 5 November 1984. Archived from the original on 2015-07-07.
  5. ^ "Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals" (PDF). Department of Economic and Social Affairs of the United Nations Secretariat. New York: United Nations. 2005.